Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Baxter International    BAX

BAXTER INTERNATIONAL (BAX)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Baxter International Inc. : Baxter's Investigational Hemophilia Treatment Yields Positive Results

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/10/2012 | 03:34pm CET
    By Saabira Chaudhuri 
 

Baxter International Inc. (BAX) said results from a study evaluating its investigational treatment for patients with hemophilia B were positive.

The medical product company's BAX 326--its investigational recombinant factor IX protein for the treatment and prophylaxis of bleeding episodes for patients with hemophilia B over 12 years of age--was recently granted orphan-drug designation by the U.S. Food and Drug Administration.

"With only one recombinant protein currently available to treat hemophilia B, it was important to focus research efforts on finding another option for patients with this debilitating disease," Lead Investigator Jerzy Windyga said. "In this study, more than 40 percent of patients using BAX 326 as a prophylactic treatment experienced no bleeds, an important finding given the potentially harmful impact of bleeding episodes for patients."

The study investigated the efficacy and safety of BAX 326 in 73 previously treated patients with severe or moderately severe hemophilia B.

Baxter noted that hemophilia B is the second most common type of hemophilia--also known as Christmas disease--and is the result of insufficient amounts of clotting factor IX, a naturally occurring protein in blood that controls bleeding. The company added that about 25,000 people world-wide, including more than 4,000 in the U.S., have been diagnosed with hemophilia B.

Baxter's profits have improved for more than a year on strong demand for its hemophilia and immunodeficiency products. Its bottom line has been less pressured by the slowdown in health-care spending, compared with some peers, because Baxter focuses on medical devices and pharmaceuticals used to treat life-threatening ailments and injuries.

In October, Baxter said its third-quarter earnings rose 1.2% as the company's margins improved, though sales were short of its prior guidance.

Shares closed Friday at $65.07 and were inactive in recent premarket trading. The stock has risen 32% so far this year.

Write to Saabira Chaudhuri at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BAXTER INTERNATIONAL
12/12 BAXTER INTERNATIONAL : to Present at 36th Annual J.P. Morgan Healthcare Conferen..
12/11 BAXTER INTERNATIONAL : to Present at the 36th Annual J.P. Morgan Healthcare Conf..
12/07 BAXTER INTERNATIONAL : Foundation, Direct Relief Mobile Health Program Connects ..
12/06 BAXTER INTERNATIONAL : Foundation and Direct Relief Mobile Health Program Connec..
12/06 BAXTER INTERNATIONAL : Foundation and Direct Relief Mobile Health Program Connec..
12/06 BAXTER INTERNATIONAL : to Present at BMO Capital Markets Prescriptions for Succe..
12/04 BAXTER INTERNATIONAL : to Present at the BMO Capital Markets Prescriptions for S..
11/30 BAXTER INTERNATIONAL : Recognized as Military Friendly Employer for Commitment t..
11/30 BAXTER INTERNATIONAL : ex-dividend day
11/24 BAXTER INTERNATIONAL : Recognized as Military Friendly Employer for Commitment t..
More news
News from SeekingAlpha
12/09 Goldman unveils sector-by-sector view for 2018 stock winners
11/20 Tracking Tweedy Browne Portfolio - Q3 2017 Update
11/14 Baxter declares $0.16 dividend
11/13 Dealing With The 'Problem' Of Owning Overvalued Dividend Growth Stocks
11/10 Tracking Dan Loeb's Third Point Portfolio - Q3 2017 Update
Financials ($)
Sales 2017 10 556 M
EBIT 2017 1 676 M
Net income 2017 1 198 M
Finance 2017 272 M
Yield 2017 0,91%
P/E ratio 2017 34,29
P/E ratio 2018 26,33
EV / Sales 2017 3,31x
EV / Sales 2018 3,06x
Capitalization 35 262 M
Chart BAXTER INTERNATIONAL
Duration : Period :
Baxter International Technical Analysis Chart | BAX | US0718131099 | 4-Traders
Technical analysis trends BAXTER INTERNATIONAL
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 16
Average target price 68,8 $
Spread / Average Target 6,3%
EPS Revisions
Managers
NameTitle
José E. Almeida Chairman, President & Chief Executive Officer
Scott Pleau Vice President-Operations
Catherine R. Smith Chief Financial Officer, Director & Executive VP
Paul E. Martin Chief Information Officer & Vice President
Marcus Schabacker Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
BAXTER INTERNATIONAL43.26%35 262
MEDTRONIC PLC13.81%110 879
C R BARD INC48.14%24 200
ZIMMER BIOMET HOLDINGS INC9.86%22 985
HOYA CORPORATION13.11%19 055
ALIGN TECHNOLOGY151.10%18 892